$0.40
0.27% yesterday
Nasdaq, Nov 25, 10:03 pm CET
ISIN
US00808Y2081
Symbol
AEMD

Aethlon Medical, Inc. Stock price

$0.40
+0.03 7.52% 1M
-0.02 4.00% 6M
-1.79 81.59% YTD
-1.24 75.41% 1Y
-26.50 98.50% 3Y
-22.20 98.22% 5Y
-3,865.85 99.99% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.00 0.27%
ISIN
US00808Y2081
Symbol
AEMD
Sector

Key metrics

Market capitalization $5.63m
Enterprise Value $-430.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.05
P/B ratio (TTM) P/B ratio 0.94
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-11.58m
Free Cash Flow (TTM) Free Cash Flow $-8.92m
Cash position $6.86m
EPS (TTM) EPS $-2.85
P/E forward negative
Short interest 2.07%
Show more

Is Aethlon Medical, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Aethlon Medical, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Aethlon Medical, Inc. forecast:

1x Buy
50%
1x Hold
50%

Analyst Opinions

2 Analysts have issued a Aethlon Medical, Inc. forecast:

Buy
50%
Hold
50%

Financial data from Aethlon Medical, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.49 0.49
40% 40%
-
-0.49 -0.49
323% 323%
-
- Selling and Administrative Expenses 8.68 8.68
7% 7%
-
- Research and Development Expense 1.91 1.91
23% 23%
-
-11 -11
4% 4%
-
- Depreciation and Amortization 0.49 0.49
40% 40%
-
EBIT (Operating Income) EBIT -12 -12
3% 3%
-
Net Profit -11 -11
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Aethlon Medical, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aethlon Medical, Inc. Stock News

Neutral
Seeking Alpha
12 days ago
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2025Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Michael Miller - Investor Relations, Rx Communications James Frakes - Interim Chief Executive Officer & Chief Financial Officer Steven LaRosa - Chief Medical Officer Conference Call Participants Marla Marin - Zacks Jeremy Pearlman - Maxim Group Operator Good day, and welcome to...
Neutral
PRNewsWire
13 days ago
Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, In...
Neutral
PRNewsWire
15 days ago
Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO , Nov. 11, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer an...
More Aethlon Medical, Inc. News

Company Profile

Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.

Head office United States
CEO James Frakes
Employees 14
Founded 1991
Website www.aethlonmedical.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today